Furthermore, increased inhibition in tumour in vivo depicted that the LNP-GEM-Mcl-1-siRNA has better anti-tumour efficacy on comparing to individual administration of GEM or Mcl-1-siRNA alone, thus proving the synergistic effect of co-delivery. The gene discussed is MCL1; the disease is neoplasm.